MingMed Biotechnology Co., Ltd. is an innovative company focusing on the development of first-in-class pharmaceutical products. The company features world class research scientists and groundbreaking discovery platforms. The core R & D team includes five national experts and several global industry leaders. The product pipeline covers ophthalmology, small molecule immuno oncology, gene editing- based immunotherapy, medical aesthetics and pet medicine. The company have more than ten ongoing projects, most of which are groundbreaking first-in-class products with clinical proof-of-concept data.
With the seminal discovery in dry AMD and dry eye pathogenesis, we aim to translate the scientific breakthrough into ophthalmic products that meet the unmet clinical demand. The goal is to launch several Traditional Chinese Medicine products in China and to advance small molecule projects to clinical stage worldwide. In ophthalmology field, we strive to become the leader in China and a competitor of the world.
Small molecule immune oncology
Focusing on a novel immune oncology target that are highly pursued by global pharmaceutical companies, we aim to maintain the lead position in pharmacology research and drug development. At the same time, we are expanding the indication into infectious diseases (antiviral), and strive to become the leading innovator.
Focusing on establishing a world class medical aesthetics R&D platform and integrating innovation with marketing insight, we aim to apply our deep understanding of Chinese consumers and Chinese distribution channels to share the dividends of the social progress and consumption upgrade, and strive to become the leader in medical aesthetic in China market.
Leveraging the cutting-edge research and development achievements of biomedical research and the deep insight into pet medicine market in China, we aim to establish a strong product pipeline and launch a serial of innovative pet medicine products, and quickly establish ourselves as the leader in China pet medicine market.
Online Contract Signing Ceremony: Xi'an Yufan Biotechnology plans to invest 100 million Yuan to build a CAR-T cell manufacturing facility
MingMed Biotechnology R&D team features world class scientists and global industry leaders. The management team is comprised of senior managers and serial entrepreneurs from pharmaceutical company, investment firm and commercial organization. The core team members have known each other for more than 20 years with long standing trust.